← Back to Search

Diagnostic Test

Head-Mounted Visual Field Testing Device for Glaucoma

N/A
Waitlist Available
Led By Brennan Eadie, MD, PhD
Research Sponsored by Brennan Eadie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ability to understand and consent to the study
Be older than 18 years old
Must not have
Seizure disorder
Previous intraocular surgery other than cataract surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new head-mounted device for visual field testing to see if it is as effective as the conventional visual field test.

Who is the study for?
This trial is for individuals who can consent and have had a visual field test indicating normal or varying degrees of glaucomatous damage. It excludes those with anxiety disorders, severe vertigo, certain past eye surgeries (except cataract surgery), pregnancy, seizure disorders, extreme refractive errors, inability to make informed decisions, significant eye opacity, cardiac pacemakers or similar devices.
What is being tested?
The study tests a new head-mounted device for visual field testing against the standard Humphrey Visual Field Analyzer in patients with different stages of glaucoma. Each participant will use both devices over five weekly visits and complete questionnaires on comfort and satisfaction.
What are the potential side effects?
Since this trial involves non-invasive testing rather than medication or surgery, side effects are minimal but may include discomfort from wearing the head-mounted device or fatigue from frequent testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand the study and agree to participate.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a seizure disorder.
Select...
I have had eye surgery, but not for cataracts.
Select...
I experience severe dizziness or problems with balance.
Select...
I have been diagnosed with secondary glaucoma.
Select...
I have an eye condition not related to glaucoma that could affect my vision.
Select...
I am able to understand and make decisions about joining the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual field differential light sensitivity
Secondary study objectives
Reproducibility of sensitivity values

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Patients will perform visual field testing with the Humphrey Visual Field Analyzer and with the custom head-mounted device.

Find a Location

Who is running the clinical trial?

Brennan EadieLead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Glaucoma
30 Patients Enrolled for Glaucoma
Brennan Eadie, MD, PhDPrincipal InvestigatorNova Scotia Healthy Authority
1 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Glaucoma
30 Patients Enrolled for Glaucoma

Media Library

Visual Field Testing (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05030714 — N/A
~50 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top